Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Results

Catalyst Pharmaceuticals Beats on EPS, Stock Down 3.43%

Catalyst Pharmaceuticals reported a strong earnings per share, exceeding expectations significantly. However, the stock fell by 3.43% in reaction, likely due to the lack of revenue details and guidance. Investors may be cautious without clearer insights into future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.31	N/A	+47.62%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management is pleased with the EPS results but did not provide specific revenue figures. They remain focused on sustaining growth.

Management highlighted strong performance in their key product.

They expressed confidence in maintaining market share moving forward.

Catalyst Pharmaceuticals Beats on EPS, Stock Down 3.43%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Beats on EPS, Stock Down 3.43%

Key numbers

Management commentary